A. Colosimo

Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia.

B. Di Camillo, A. Orlacchio, F. Ricci, 2011, Cancer biomarkers : section A of Disease markers.

ZAP-70, IgVh ,an dcytogenetic sfo rassessing prognosis in chronic lymphocytic leukemia

F. Ricci, M. Nichelatti, A. Tedeschi, 2010 .

ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.

F. Ricci, M. Nichelatti, A. Tedeschi, 2010, Cancer biomarkers : section A of Disease markers.

Molecular characterization of post‐transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients

D. Rossi, G. Gaidano, D. Capello, 2009, The Journal of pathology.

YrxA Is the Transcriptional Regulator That Represses De Novo NAD Biosynthesis in Bacillus subtilis

A. Albertini, A. Colosimo, I. Marinoni, 2005, Journal of bacteriology.

Double supernumerary isochromosome 4p in acute myelomonocytic leukemia.

A. Colosimo, B. Scarpati, C. Cesana, 2010, Leukemia research.

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

F. Ricci, M. Nichelatti, R. Cairoli, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.